Cleveland BioLabs, Inc. (CBLI)
Stock Price:
$2.77 USD
0.09 (3.36%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
36.06M |
| Revenue (ttm) |
857,832 |
| Net Income (ttm) |
-2.12M |
| Shares Out |
13.02M |
| EPS (ttm) |
-0.18 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$2.77 |
| Previous Close |
$2.68 |
| Change ($) |
0.09 |
| Change (%) |
3.36% |
| Day's Open |
2.63 |
| Day's Range |
2.60 - 3.21 |
| Day's Volume |
1,758,194 |
| 52-Week Range |
0.50 - 5.43 |
More Stats
| Market Cap |
36.06M |
| Enterprise Value |
32.29M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.02M |
| Float |
5.67M |
| EPS (basic) |
-0.18 |
| EPS (diluted) |
-0.18 |
| FCF / Share |
-0.17 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
172,740 |
| Short Ratio |
1.86 |
| Short % of Float |
3.04% |
| Beta |
0.71 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
42.03 |
| PB Ratio |
n/a |
| Revenue |
857,832 |
| Operating Income |
-1.84M |
| Net Income |
-2.12M |
| Free Cash Flow |
-1.97M |
| Net Cash |
3.77M |
| Net Cash / Share |
0.29 |
| Gross Margin |
-63.30% |
| Operating Margin |
-213.98% |
| Profit Margin |
-246.60% |
| FCF Margin |
-229.43% |
| ROA |
-32.02% |
| ROE |
-78.98% |
| ROIC |
2,331.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
40.0
Current: $2.77
High
40.0
Target: 40.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 1.11 | 1.14 | 1.95 | 3.52 | 2.71 | 3.70 | 8.49 | 3.57 | 8.79 | 15.33 |
| Revenue Growth | -2.18% | -41.58% | -44.62% | 29.92% | -26.84% | -56.39% | 137.71% | -59.38% | -42.67% | - |
| Gross Profit | 1.11 | 1.14 | 1.95 | 3.52 | 2.71 | 3.70 | 8.49 | 3.57 | 8.79 | 15.33 |
| Operating Income | -2.36 | -4.80 | -5.60 | -6.36 | -10.79 | -14.42 | -23.08 | -30.05 | -25.11 | -10.74 |
| Net Income | -2.65 | -3.61 | -9.71 | -2.66 | -12.64 | 1.63 | -17.26 | -18.23 | -4.01 | -26.37 |
| Shares Outstanding | 11.30 | 11.29 | 11.19 | 10.99 | 7.06 | 2.70 | 2.25 | 1.87 | 1.63 | 1.31 |
| Earnings Per Share | -0.23 | -0.32 | -0.87 | -0.24 | -1.79 | 0.60 | -7.67 | -9.75 | -2.40 | -20.20 |
| Operating Cash Flow | -2.66 | -4.61 | -6.61 | -5.04 | -12.08 | -14.46 | -23.10 | -20.65 | -16.91 | -5.90 |
| Capital Expenditures | 0.05 | 0.01 | - | 0.19 | 0.01 | -0.02 | -0.14 | -0.18 | -0.66 | -0.47 |
| Free Cash Flow | -2.61 | -4.61 | -6.61 | -4.85 | -12.07 | -14.48 | -23.24 | -20.83 | -17.56 | -6.36 |
| Cash & Equivalents | 1.58 | 4.12 | 8.79 | 15.25 | 19.66 | 4.80 | 13.28 | 29.86 | 28.39 | 11.38 |
| Total Debt | - | - | - | - | - | 4.15 | 7.56 | 0.17 | - | - |
| Net Cash / Debt | 1.58 | 4.12 | 8.79 | 15.25 | 19.66 | 0.66 | 5.71 | 29.69 | 28.39 | 11.38 |
| Assets | 2.04 | 4.53 | 9.63 | 15.96 | 20.88 | 9.81 | 14.70 | 32.01 | 32.13 | 19.89 |
| Liabilities | 1.05 | 0.92 | 2.22 | 3.11 | 5.84 | 8.03 | 13.11 | 11.52 | 9.88 | 32.39 |
| Book Value | -4.06 | -1.45 | 2.20 | 7.52 | 9.89 | -1.61 | -9.52 | 6.33 | 9.06 | -15.70 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cleveland BioLabs, Inc. |
| Country |
United States |
| Employees |
7 |
| CEO |
Christopher Zosh |
Stock Information
| Ticker Symbol |
CBLI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CBLI |
| IPO Date |
July 21, 2006 |
Description
Cleveland BioLabs, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.